Inovio Pharmaceuticals
126 hedge funds and large institutions have $113M invested in Inovio Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 16 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
0% more funds holding
Funds holding: 126 → 126 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
0.12% less ownership
Funds ownership: 2.77% → 2.65% (-0.12%)
20% less capital invested
Capital invested by funds: $142M → $113M (-$28.4M)
26% less call options, than puts
Call options by funds: $449K | Put options by funds: $610K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.44M |
| 2 |
BlackRock
New York
|
+$1.64M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$804K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$690K |
| 5 |
Squarepoint
New York
|
+$667K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$2.53M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.17M |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.96M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$848K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$803K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IG
126
ING Group
Amsterdam,
Netherlands
| – | -$330K | -5,833 | Closed |
|
|
EMG
127
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$308K | -5,442 | Closed |
|
|
SIP
128
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$287K | -5,085 | Closed |
|
|
VF
129
Virtu Financial
New York
| – | -$196K | -3,469 | Closed |
|
|
BCM
130
BlueCrest Capital Management
St Helier,
Jersey
| – | -$118K | -2,092 | Closed |
|
|
LCM
131
Laurion Capital Management
New York
| – | -$116K | -2,058 | Closed |
|
|
CSS
132
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$96K | -1,695 | Closed |
|
133
Jane Street
New York
| – | -$74K | -1,310 | Closed |
|
|
TRCT
134
Tower Research Capital (TRC)
New York
| – | -$65K | -1,151 | Closed |
|
|
KF
135
Krilogy Financial
St. Louis,
Missouri
| – | -$2K | -42 | Closed |
|
|
CG
136
Cutler Group
San Francisco,
California
| – | -$1K | -25 | Closed |
|
|
PHK
137
Point72 Hong Kong
Hong Kong
| – | -$1K | -21 | Closed |
|
|
FHA
138
Flagship Harbor Advisors
Boston,
Massachusetts
| – | +$110 | +2 | New |
|
INO Hedge Fund Activity: Q2 2018 in Review
126 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2018, worth a combined $113M — down 20% from $142M a quarter earlier.
Fund positioning in INO was balanced in Q2 2018: 16 funds opened new positions, 16 closed out, 35 added to existing stakes and 31 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $2.44M. The largest seller was State Street, cutting an estimated $2.53M.
- 126 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $113M of Inovio Pharmaceuticals stock for Q2 2018, down 20% quarter-over-quarter.
- 16 funds opened new Inovio Pharmaceuticals positions in Q2 2018 and 16 closed out, a net change of 0 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2018 was ARK Investment Management, an estimated $2.44M added.
- The largest Inovio Pharmaceuticals seller in Q2 2018 was State Street, an estimated $2.53M sold.
Based on aggregated 13F filings for Q2 2018.